1. Generics Bulletin
  2. >>Products
  3. >>Generics

Zydus Becomes A Part Of History As It Loses On US Canagliflozin Patents

Three US Patents Not Invalid, New Jersey Court Rules

 
• By Dean Rudge

ANDA sponsor Zydus Cadila has failed to convince a US district court that three patents shielding the Invokana/Invokamet brands were invalid, as it became a little part of history in one of the major trials to be held amid the coronavirus pandemic.

Gavel
Wolfson’s opinion is currently under seal • Source: Shutterstock

Zydus Cadila is facing at least a six-year wait to introduce its proposed generic version of Janssen/Mitsubishi’s former blockbuster Invokana (canagliflozin) and Invokamet (canagliflozin/metformin) tablets, with a US district court upholding as valid three US patents shielding the branded treatments for diabetes.

The order handed down by district court judge Freda Wolfson was the culmination of “the first virtual Hatch-Waxman litigation to be tried remotely from start to finish in the US District Court for the District of New Jersey, and one

More from Generics

More from Products

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 
• By Urtė Fultinavičiūtė

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.